Gallium formulation for the treatment and prevention of infectious diseases

Inventors

Ohtake, Satoshi • Truong-Le, Vu • Lechuga-Ballesteros, David • Yee, Luisa • Pham, Binh V • Martin, Russell • Saxena, Atul

Assignees

Aridis Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8637090-B2

Patent

Publication Date

2014-01-28

Expiration Date


Abstract

A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as Staphylococcus aureus, Rhodococcus equi, Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a formulation containing gallium (III), in a pharmaceutically acceptable salt or complex thereof.

Core Innovation

The disclosed invention relates to gallium (III) anti-infective compositions and methods for treating and preventing infections in a subject. The compositions comprise a solution or a dry powder derived from the solution of an anti-microbially effective concentration of gallium (III) and citrate, with a fixed citrate-to-gallium molar ratio of 2:1.

The compositions are formulated as pharmaceutically acceptable gallium salts and/or complexes delivered as inhalable aerosols, including liquid formulations and dry powder formulations. Counterion and complexing-agent roles are addressed, including citrate and other agents, and solubility and precipitation behavior is controlled by the citrate-to-gallium molar ratio.

The invention further includes physical and pharmaceutical constraints for the dry powder, including aerosol characteristics such as MMAD and mean particle size, and delivered-dose parameters. Characterization and support described in the document include solubility in plasma, aerosol droplet and powder particle size distributions, XRD and SEM morphology and crystallinity, in vitro bacterial growth inhibition and MIC, and lung residence time and pharmacokinetics in rodents for the pulmonary administration context.

Claims Coverage

The document includes one independent claim. Its coverage is centered on a gallium (III)-and-citrate formulation with a fixed citrate-to-gallium molar ratio of 2:1, administered as either a solution or a dry powder derived from that solution.

Fixed citrate-to-gallium ratio gallium(III)-citrate anti-infective formulation

A method for treating an infection by administering a pharmaceutical formulation comprising a solution, or a dry powder derived from said solution, of an anti-microbially effective concentration of gallium (III) and citrate, wherein the molar ratio of citrate to gallium is 2:1.

Solution delivered in aerosol form

The method wherein the solution is in aerosol form.

Dry powder particle size and MMAD constraints

The method wherein the powder has a pharmaceutically acceptable mass median aerodynamic diameter (MMAD) and a mean particle size lower than 10 micrometers.

Non-turbid bolus addition to biological fluids

The method wherein adding a bolus volume of a pharmaceutical formulation to a tenfold greater volume of human plasma or extracellular lung fluid does not cause turbidity, as measured after adding the solution to the biological fluid.

Infection scope defined by gram-negative and gram-positive bacteria

The method wherein the infection includes a specified list of gram-negative bacteria and/or a specified list of gram-positive bacteria.

Selected additional complexing/iron-chelating agents

The method wherein the formulation includes a selected complexing agent comprising one or more of mannitol, maltolate, protoporphyrin IX, protoporphyrin IX derivatives, siderophores of the catecholate groups, siderophores of the hydroxamate groups, siderophores of the hydroxycarboxylate groups, bacterial hemophores, or an iron chelator.

Overall, the claims coverage centers on administering a gallium (III)-and-citrate pharmaceutical formulation with a fixed citrate-to-gallium molar ratio of 2:1, with dependent claims refining the delivery form, dry-powder aerodynamic and particle size characteristics, turbidity behavior in biological fluids, infection scope, and optional complexing or iron-chelating agents.

Stated Advantages

Turbidity and precipitation do not occur upon bolus addition to human plasma or extracellular lung fluid.

The formulation provides anti-microbial effectiveness for treating and preventing infections in a subject.

Documented Applications

Treating and preventing pulmonary infections, including infections associated with cystic fibrosis and chronic colonizers, using inhalable aerosol or dry powder gallium (III) and citrate formulations.

Treating infections involving gram-negative and gram-positive bacteria, including cystic fibrosis-associated Pseudomonas aeruginosa and other listed bacterial species.

Treating infections relevant to respiratory conditions referenced in the document context, including bronchiectasis, COPD, and ventilator-associated conditions.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.